Stephen Foley: ObamaCare is bad news for Big Pharma


US Outlook: It has been a delight to see the good citizens of the UK getting all atwitter in defence of the National Health Service, in the face of so much bad-mouthing here in the US. If you can find an American, and disabuse them of the notion that the British government runs "death panels" that decide who gets life-saving treatment, that might help bring the healthcare debate here back into the realm of the real.

I still can't quite get my head around the idea we have to weigh our health against our wallets in this country, but this is the system that opponents of change say is the best in the world, despite all statistical evidence to the contrary.

It is certainly the best system in the world for the healthcare companies, whose margins in the US are fatter than they are anywhere else. Two of the UK's biggest firms, the pharmaceuticals companies GlaxoSmithKline and AstraZeneca, get around 40 per cent of their revenues from the US, making them critical players in the debate here – and meaning that the outcome of Barack Obama's fight for reform has some significant financial implications for UK shareholders.

The pharmaceuticals industry thinks it is playing a canny game. Early on, via its US lobby group PhRMA, it shook hands on a deal with the White House, pledging to cut the costs of drugs for senior citizens on federal health insurance by a total of $80bn (£48bn), and promising not to fund anti-reform ads as they have done in the past.

In return, they got what looks to some Democrats like an impressive list of concessions. There will be no congressional or White House push to allow the importation of cheaper drugs from Canada, and no other federal pressure for rebates that could push the cost of reform to the industry above that $80bn. With these promises in the bank, investors in drug firms rather think that the expansion of health insurance will actually lead to more people using their products, which would more than make up for the loss of margin.

Actually, the drug firms are much more likely to be losers – and not just because the pact with the White House is showing signs of breaking down. Within weeks the President suggested that he might be able to negotiate more than the $80bn from the industry, and as more details of the secret deal have leaked this week, anger among congressional Democrats has prompted even more equivocation from the White House.

Even if President Obama cuts the drug industry loose, as long as he does it at the last minute, when there will be no time left to lobby, he will have achieved his objective of neutering the industry.

There's a whole list of other worries for the world's largest pharmaceuticals companies, all stemming from the fact that President Obama is fixated on getting the cost of healthcare down. One way or another, that means slimmer margins for GlaxoSmithKline, AstraZeneca and their rivals. The betting is still that health insurance reform will pass in some form, either with a government-run scheme that will pull in people who fall out of employee-sponsored plans, or private-sector cooperatives. Whichever is the case, there ought to be big new players in what is currently a fragmented market, whose buying power can help drive down the cost of medicines.

And, before the current healthcare legislation began to take shape, another major development occurred that increasingly worries pharmaceuticals executives. The federal government this year set aside $1.1bn to fund "comparative effectiveness research". This will go towards studying whether expensive brand-name medicines are really any better than generic copies, and preventing the wasteful use of drugs that might prove to be ineffective on some types of patient.

Most importantly, the research will be a useful counter to Big Pharma-funded research studies, and the boondoggle propaganda of their super-remunerated salesforces.

The pharmaceuticals giants are switching their expansion plans as fast as they can to emerging markets, where richer populations are spending more on health. The trouble is, profits look set to erode faster in their largest market.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksAn introduction to the ground rules of British democracy
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Experienced Recruitment Consultant

£20000 - £40000 per annum + OTE + Incentives + Benefits: SThree: Established f...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE 40/45k + INCENTIVES + BENEFITS: SThree: The su...

Recruitment Genius: Collections Agent

£14000 - £16000 per annum: Recruitment Genius: This company was established in...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE 40k: SThree: SThree are a global FTSE 250 busi...

Day In a Page

Isis profits from destruction of antiquities by selling relics to dealers - and then blowing up the buildings they come from to conceal the evidence of looting

How Isis profits from destruction of antiquities

Robert Fisk on the terrorist group's manipulation of the market to increase the price of artefacts
Labour leadership: Andy Burnham urges Jeremy Corbyn voters to think again in last-minute plea

'If we lose touch we’ll end up with two decades of the Tories'

In an exclusive interview, Andy Burnham urges Jeremy Corbyn voters to think again in last-minute plea
Tunisia fears its Arab Spring could be reversed as the new regime becomes as intolerant of dissent as its predecessor

The Arab Spring reversed

Tunisian protesters fear that a new law will whitewash corrupt businessmen and officials, but they are finding that the new regime is becoming as intolerant of dissent as its predecessor
King Arthur: Legendary figure was real and lived most of his life in Strathclyde, academic claims

Academic claims King Arthur was real - and reveals where he lived

Dr Andrew Breeze says the legendary figure did exist – but was a general, not a king
Who is Oliver Bonas and how has he captured middle-class hearts?

Who is Oliver Bonas?

It's the first high-street store to pay its staff the living wage, and it saw out the recession in style
Earth has 'lost more than half its trees' since humans first started cutting them down

Axe-wielding Man fells half the world’s trees – leaving us just 422 each

However, the number of trees may be eight times higher than previously thought
60 years of Scalextric: Model cars are now stuffed with as much tech as real ones

60 years of Scalextric

Model cars are now stuffed with as much tech as real ones
Theme parks continue to draw in thrill-seekers despite the risks - so why are we so addicted?

Why are we addicted to theme parks?

Now that Banksy has unveiled his own dystopian version, Christopher Beanland considers the ups and downs of our endless quest for amusement
Tourism in Iran: The country will soon be opening up again after years of isolation

Iran is opening up again to tourists

After years of isolation, Iran is reopening its embassies abroad. Soon, there'll be the chance for the adventurous to holiday there
10 best PS4 games

10 best PS4 games

Can’t wait for the new round of blockbusters due out this autumn? We played through last year’s offering
Transfer window: Ten things we learnt

Ten things we learnt from the transfer window

Record-breaking spending shows FFP restraint no longer applies
Migrant crisis: UN official Philippe Douste-Blazy reveals the harrowing sights he encountered among refugees arriving on Lampedusa

‘Can we really just turn away?’

Dead bodies, men drowning, women miscarrying – a senior UN figure on the horrors he has witnessed among migrants arriving on Lampedusa, and urges politicians not to underestimate our caring nature
Nine of Syria and Iraq's 10 world heritage sites are in danger as Isis ravages centuries of history

Nine of Syria and Iraq's 10 world heritage sites are in danger...

... and not just because of Isis vandalism
Girl on a Plane: An exclusive extract of the novelisation inspired by the 1970 Palestinian fighters hijack

Girl on a Plane

An exclusive extract of the novelisation inspired by the 1970 Palestinian fighters hijack
Why Frederick Forsyth's spying days could spell disaster for today's journalists

Why Frederick Forsyth's spying days could spell disaster for today's journalists

The author of 'The Day of the Jackal' has revealed he spied for MI6 while a foreign correspondent